Posted by Michael Wonder on 06 Jul 2021
Knight Therapeutics announces Health Canada approval for Nerlynx (neratinib) to treat HER2 positive metastatic breast cancer
6 July 2021 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2 over-expressed/amplified breast cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting.
The approval was based on results of the global Phase 3 NALA trial.
Knight has the exclusive right to commercialise Nerlynx in Canada under the terms of a license agreement entered into with Puma Biotechnology.
